CQN-ALTER-DOMUS
10.5.2022 11:48:12 CEST | Business Wire | Press release
Third bullet in the body of the release should read: "Tailored benchmarking against peers and operational support" (instead of "Tailored benchmarking against peers and operational advisory")
The updated release reads:
ALTER DOMUS LAUNCHES INDUSTRY-LEADING ESG REPORTING SOLUTION FOR ALTERNATIVE INVESTMENT MANAGERS
Fund administrator unveils comprehensive and innovative ESG solution that provides regulatory and signatory support for clients
Alter Domus, a leading provider of integrated solutions for the alternative investment industry, today announced it has launched an industry-leading Environmental, Social & Governance (ESG) reporting solution.
Despite a lack of standardized ESG models available, demand for ESG data is booming.1 This trend has placed additional strain on alternatives managers who are increasingly fielding ESG data requests from investors, regulators, and non-governmental organizations without a clear directive on how to report or share this data.
Designed specifically for alternative assets, Alter Domus’ ESG Reporting Solution is a cloud-based digital platform that provides comprehensive, tailored reports for clients that collect, store, and disseminate corporate ESG data. Alter Domus’ ESG Reporting Solution will be accessible through an online, user-friendly portal that ensures secure access and management of client data.
Other features of Alter Domus’ ESG Reporting Solution include:
- Scoring and ratings for a fund or portfolio based on internationally recognized standards
- Data analysis that can be shared with stakeholders, including regulators for disclosure, compliance, and other reporting purposes
- Tailored benchmarking against peers and operational support
“Today’s announcement underscores Alter Domus’ commitment to developing and offering the most innovative products that our clients need at a global scale,” said Alex Traub, Chief Commercial Officer. “ESG has become an important part of investment philosophies for investors at every level, and we expect this trend to continue even further as ESG becomes more standardized and mainstream with alternative managers.”
“We have heard from our clients globally about the need for a standardized ESG reporting framework and solution that can be integrated across all of their operations seamlessly,” said Antonis Anastasiou, Managing Director of the Alter Domus Management Company S.A. “We worked to develop this solution that helps our clients not only navigate the complexities of ESG regulation, but to also provide their own investors with the types of reporting they need.”
For its part, and as a growing organization with an increasingly global footprint, Alter Domus ensures that ESG factors are considered as standard practice in all strategic business planning and decision making. Further, Alter Domus is a signatory of the United Nations-supported Principles for Responsible Investment, and aligned with The World Economic Forum (WEF) Measuring Stakeholder Capitalism; Towards Common Metrics and Consistent Reporting of Sustainable Value Creation framework.
Over the last 12 months, Alter Domus has seen increasing demand for alternative investments, particularly in Europe and the United States. Having doubled their assets under administration in that time, Alter Domus is at the forefront of delivering timely, technology-driven solutions to alternative asset managers, lenders, and asset owners globally.
About Alter Domus
Alter Domus is a leading provider of integrated solutions, serving private equity, real assets and debt capital markets sectors with more than 3,600 employees across 36 offices globally. Solely dedicated to alternatives, Alter Domus offers fund administration, corporate services, depositary services, capital administration, transfer pricing, domiciliation, management company services, loan administration, agency services, trade settlement and CLO manager services. Find out more at www.alterDomus.com .
____________________
1
Opimas Research: http://www.opimas.com/research/547/detail/
View source version on businesswire.com: https://www.businesswire.com/news/home/20220502005016/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From AI to Autonomous Networks: Mobileum Spark Highlights the Next Frontier of Telecom Intelligence15.10.2026 09:00:00 CEST | Press release
Industry leaders get together to explore how trusted AI, Agentic Intelligence and automation are transforming risk management, accelerating autonomous network operations and unlocking new opportunities for value creation Mobileum Inc. ("Mobileum"), a leading global provider of telecom analytics and network solutions, brought together telecom operators and industry leaders during its Mobileum Spark events series in Lisbon (Portugal) and Frankfurt (Germany), to explore how Artificial Intelligence (AI), Agentic AI and automation are transforming network operations and accelerating the evolution toward autonomous networks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015172815/en/ Telecom operators, industry leaders, and Mobileum experts at Mobileum Spark 2026. Focused on Risk Management & Fraud Prevention and Network Testing & Assurance, the events featured customer-led discussions, expert insights, and real-world use case
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release
Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
